Speaker 1: Bloomberg Audio Studios, podcasts, radio news.
Speaker 2: The Stock Movers Report, your roundup of companies making moves
Speaker 2: in the stock market, harnessing the power of Bloomberg Data.
Speaker 3: Scarla Flul Paul Sweeney live here on a Bloomberg in
Speaker 3: Act Proper Studio streaming line on YouTube as well. Let's
Speaker 3: see what some stocks on the move today in a mixtape.
Speaker 3: It's good that they need to Sokova Bloomberg News.
Speaker 4: They need to.
Speaker 3: What are you looking at.
Speaker 1: Let's start with some gainer as we have Eli Lilly today.
Speaker 1: Now it's about two percent, but we so much bigger
Speaker 1: gain in earlier trading. Once the market opened, it jumped
Speaker 1: as much as three point four percent. Of course, it
Speaker 1: is coming of pretty strong for year guidance. They raised
Speaker 1: it and both for their weight loss drug and diabetes drug.
Speaker 1: What we're seeing is that they're taking bigger and bigger
Speaker 1: market share of that weight loss and diabetes market that
Speaker 1: everyone has been competing about. Now they account for fifty
Speaker 1: eight percent of that market. And this is the weight
Speaker 1: loss one, which obviously they compete directly with novels Ozenpi
Speaker 1: and wi Goovy, deabetes drug Munjaro, and their zip Bound
Speaker 1: which is the weight loss one. They outpass expectations by
Speaker 1: a combine nearly one point three billion, so really strong
Speaker 1: results there. That said, the stock is actually up only
Speaker 1: five percent before the earnings, and obviously a little bit more,
Speaker 1: but we're seeing some optimism from investors. Mitzuhui is saying,
Speaker 1: it's very clear that Eli Lily is.
Speaker 4: Winning the weight loss race.
Speaker 1: Obviously, now we're talking about different, more advanced drugs, so
Speaker 1: that potentially we're entering a whole new leg in the competition.
Speaker 1: But in this particular race, Eli Lily's lead is becoming clear.
Speaker 3: The question I asked in the surveillance chat box, and
Speaker 3: I don't know the answer. I haven't seen the reporting
Speaker 3: on it. If there's for someone out there who would
Speaker 3: benefit from the weight loss struggle, why aren't they taking it?
Speaker 4: Maybe because it's a shot?
Speaker 3: Okay, I was going to ask, is it because they
Speaker 3: don't want to take shots?
Speaker 2: Is it cost?
Speaker 3: Is availability?
Speaker 4: Is it side effects?
Speaker 3: Because you just wonder why more people aren't using it.
Speaker 3: I don't know the answer to that, but I guess
Speaker 3: it's probably the combination of all that.
Speaker 4: Yeah, But I'm guessing the simplest answer is the right answer,
Speaker 4: which is cost.
Speaker 1: Yeah, yeah, yeah, very good.
Speaker 3: All right.
Speaker 2: Us, you have Force, you.
Speaker 1: Have Comcasts, which we're seeing an interesting reaction in markets
Speaker 1: if you actually pre market training, we saw a positive reaction.
Speaker 4: The earnings report is mixed.
Speaker 1: Obviously, the company lost one hundred thousand subscribers, which is less.
Speaker 4: Than what analysts were expected.
Speaker 1: But if we zoom out, the trajectory has been really bad.
Speaker 1: This is the tenth quarter in a row where they
Speaker 1: see domestic world round customer losses.
Speaker 4: That said, as we said, unless.
Speaker 1: We're expecting one hundred and forty thousand, so we're seeing
Speaker 1: some optimism there. A third quarter revenue fail by about
Speaker 1: three percent, and it's also beating estimates, so again less feared,
Speaker 1: but competition in that space has been heating up. Obviously,
Speaker 1: people are moving away cutting their court in favor for
Speaker 1: streaming services. Obviously people are their Internet platons over by Verizon,
Speaker 1: but timobau and that strong competition there. Comcast is one
Speaker 1: of the big losers this year. Company is down nearly
Speaker 1: thirty percent here to date. There have been a lot
Speaker 1: of changes, a lot of volatility there, and even earning
Speaker 1: support that was less bad than feared cannot bring optimism
Speaker 1: at least on a day like today.
Speaker 4: All right, let's get to a mag seven name. Meta.
Speaker 1: Yeah, Meta has been the story of the last twenty
Speaker 1: four hours. Now, it's down nearly twelve percent a fell
Speaker 1: fourteen percent in earlier trading. Of course, it's coming off
Speaker 1: concerns of AI spending. The Facebook parents report the third
Speaker 1: quarter earnings results gave outlook, but the main thing everyone
Speaker 1: is looking at is Mark Zuckerberg warned that meta platforms
Speaker 1: will need to spend even more aggressively. We had some
Speaker 1: news today on Bloomberg that they aim to sell at
Speaker 1: twenty five billion of investment grade bonds and this might
Speaker 1: be their biggest largest in twenty twenty five, so clearly
Speaker 1: things are moving fast.
Speaker 4: That said, the earnings report, their revenue was strong.
Speaker 1: Their ads revenue, which is kind of the kind of
Speaker 1: their main source of income, is strong. But we saw
Speaker 1: a lot of downgrades coming.
Speaker 4: At least two. One is Oppenheimer.
Speaker 1: Saying that investors will strugger to rationalize those prices at.
Speaker 4: Least until twenty twenty seven.
Speaker 1: And also we saw analysts on the code saying that
Speaker 1: they're obviously concerned about this, so a lot of pressure on.
Speaker 4: The store Google.
Speaker 3: They don't mind the spending if your meta a little
Speaker 3: bit concerned about it.
Speaker 2: The Stock Mover's report from Bloomberg Radio. Check back with
Speaker 2: us throughout the day for the latest roundup of companies
Speaker 2: making news on Wall Street and for the latest market
Speaker 2: moving headlines. Listen to Bloomberg Radio Live catches on YouTube,
Speaker 2: Bloomberg dot com, and on Applecarplay and Droid Auto with
Speaker 2: the Bloomberg Business app mm HM